From Resverlogix, my guess is that Michael Sweeney and Jan Johansson would be involved in FDA discussions for sure. Possibly Norman Wong and Ewelina Kulikowski too. There could also be involvement from the chairs and members of the respective clinical steering committees depending on if it a meeting on cardio, renal, neurodegenerative, or a combination. 

https://www.resverlogix.com/about/team

https://www.resverlogix.com/science-and-programs/clinical#betonmace